Intercept Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Fibrosis of the liver, the process of chronic scarring leading to cirrhosis, can result from viral infections such as hepatitis, as well as alcoholism and obesity-diverse factors that historically have made it difficult to treat and impossible to prevent, much less reverse. But that's what Intercept Pharmaceuticals Inc. believes it can do with its lead compound, INT-747.
You may also be interested in...
X-Ceptor Therapeutics Inc.
The field of nuclear receptor drug discovery boasts few industrial-strength programs. X-Ceptor Therapeutics Inc., a 1999 spin-out from Ligand Pharmaceuticals Inc., is one of the few dedicated players in this area of drug discovery.
Gloucester Pharmaceuticals Inc.
Two subtypes of T-cell mediated lymphomas have been very difficult to treat using the existing cytotoxic chemotherapy treatments. CTCL and peripheral T-cell lymphoma (PTCL) patients receiving chemotherapy may experience severe, dose-limiting toxicities and develop resistance to the therapy. Gloucester Pharmaceuticals Inc. is developing a treatment that potentially is more effective than chemo, the company says, and the National Institutes of Health is backing its development.
Hemobiotech Inc.
Hemobiotech Inc. was formed to commercialize HBOC technology originally developed at Texas Tech University. By modifying hemoglobin with ATP, glutathione and adenosine, the company claims it eliminates toxicity and vasoactivity. The company also has evidence that HemoTech may have the added benefit of inducing erythropoiesis.